MOSCOW (Reuters) – Russia has granted approval for clinical trials to be held for the Chinese COVID-19 vaccine Ad5-Ncov involving 8,000 volunteers, the Interfax news agency reported on Monday.
Ad5-nCoV is a vaccine candidate co-developed by CanSino Biologics and a Chinese military-backed research unit.
(Writing by Tom Balmforth; editing by Louise Heavens)
